亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Method to Obtain Hematopoietic Stem Cells

详细技术说明
None
*Abstract

New method to obtain hematopoietic stem cells with increased engraftment potential to treat blood-based cancers.

*Principal Investigation

Name: Shannon Buckley

Department: University of Leuven


Name: Catherine Verfaillie, MDm, PhD, Professor

Department: University of Leuven

附加资料
Patent Number: US20110311492A1
Application Number: US13132283A
Inventor: Verfaillie, Catherine | Buckley, Shannon Mychel | Khurana, Satish
Priority Date: 1 Dec 2008
Priority Number: US20110311492A1
Application Date: 21 Jul 2011
Publication Date: 22 Dec 2011
IPC Current: A61K003512 | A61K003802 | A61K003818 | A61P000700 | C12N00050789
US Class: 4240937 | 435375 | 5140076 | 5140135
Title: MAINTENANCE/EXPANSION OF HSC's
Usefulness: MAINTENANCE/EXPANSION OF HSC's
Summary: The methods are useful for maintaining/expanding HSCs; preparing a composition; and treating a non-malignant blood disorder, a metabolic storage disorder, or cancer. The cell, composition, HSCs which have been contacted with the factors, and the factors are useful in medical therapy for treating a non-malignant blood disorder, a metabolic storage disorder, or cancer. The non-malignant blood disorder is selected from immunodeficiencies comprising severe combined immunodeficiency (SCID), Fanconi's anemia, aplastic anemia, or congenital hemoglobinopathy. The metabolic storage disease is Hurler's disease, Hunter's disease, or mannosidosis. Cancer is selected from hematological malignancies comprising acute leukemia, chronic leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, or non-hematological cancer. The chronic leukemia is myeloid or lymphoid. The lymphoma is Hodgkin's or non-Hodgkin's lymphoma. The non-hematological cancer is breast carcinoma, colon carcinoma, neuroblastoma, or renal cell carcinoma (all claimed).
Novelty: Maintaining/expanding hematopoietic stem cells (HSCs) by contacting HSCs with exogenous factors, e.g. tissue factor pathway inhibitor (TFPI) or defensin related cryptdin 3 (DEFCR3) or its biologically active fragment or derivative
主要类别
诊断/治疗
细分类别
癌症/肿瘤
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备